Background-Financial concerns are often cited by physicians as a barrier to administering routinely recommended vaccines to adults. The purpose of this study was to assess (1) perceived payments and profit from administering recommended adult vaccines and (2) vaccine purchasing practices among general internal medicine (GIM) and family medicine (FM) practices in the United States.
Results-Of 242 practices approached, 43% (n=104) completed the survey. Reported payment levels and perceived profit varied by payer type. Only for preferred provider organizations did a plurality of respondents report profiting on adult vaccination services. Over half of respondents reported losing money vaccinating adult Medicaid beneficiaries. One-quarter to one-third of respondents reported not knowing about Medicare Part D payment levels for vaccine purchase and vaccine administration, respectively. Few respondents reported negotiating with manufacturers or insurance plans on vaccine purchase prices or payments for vaccination.
Conclusions-Practices vaccinating adults may benefit from education and technical assistance related to vaccine financing and billing and greater use of purchasing strategies to decrease upfront vaccine cost. Physicians providing care to both publicly-and privately-insured patients may receive widely divergent payments for administering the same vaccine depending on the patient's insurance benefits. Generally, private insurance plans establish set payments for vaccine purchase and administration. Providers contracting with the plan agree to accept these rates, although negotiation is possible. (8) Most plans specify provider types and sites of care for which vaccination is covered; payments may vary by provider and site. Payments under original Medicare (Part B), which covers influenza and pneumococcal vaccination, hepatitis B vaccination for certain at-risk persons, and tetanus vaccination for wound care only, are established at the federal level with geographic adjustments.(9) Medicaid fee-for-service payments are determined by each state.(10) For Medicare Part D, a prescription drug benefit that covers all ACIP-recommended vaccines not covered under Part B, the payment structure is similar to private insurance: multiple Part D plans operate in each state and each plan establishes payments for vaccination. Medicaid managed care plans operate similarly.
Keywords
The Patient Protection and Affordable Care Act of 2010 (ACA) includes several elements designed to increase access to preventive services including vaccines. The ACA requires coverage for ACIP-recommended vaccines with no patient cost-sharing when vaccines are administered by in-network providers to beneficiaries of non-grandfathered private health plans or Medicaid beneficiaries who gained eligibility through ACA program expansions. (11) (In 2016, 77% of workers with employer-based health insurance were covered by nongrandfathered plans.)(12) It also specified a temporary increase in Medicaid payments for certain primary care services, including vaccine administration, provided by certain types of physicians; services provided from January 1, 2013-December 31, 2014 were paid at the lower of the provider's actual charge for the service or the respective Medicare Part B fee schedule rate, which is substantially greater than Medicaid vaccine administration payments in most states. (10, (13) (14) The ACA does not include provisions related to private insurance payments to physicians or physician practices for vaccination, nor make any significant changes to vaccination benefits coverage or payment rates for Medicare beneficiaries or persons who were Medicaid-eligible prior to the ACA Medicaid expansion that began in January 2014.
In 2013, we conducted a survey on adult vaccination billing and financing among family medicine (FM) and general internal medicine (GIM) physicians.(15) Significant proportions of respondents reported being unable to answer questions on vaccine purchase and administration payments. Since financial concerns are a commonly-reported barrier to adult vaccination, we designed the current study to better understand vaccine financing issues in physician practices serving adult patients. Our primary objectives were to assess among knowledgeable practice staff (1) perceived payments and profit from administering vaccines routinely recommended for adults and (2) vaccine financing and purchasing practices among FM and GIM in the U.S.
Methods

Study design
The study comprised a telephone survey of personnel working in FM and GIM practices who were considered knowledgeable about vaccine financing and billing. The 553 of 839 physicians (66%) that responded to our previous survey (15) were asked to provide contact information for someone at their practice who had direct experience with vaccine billing and could report the practice's vaccine financing experiences. Overall, 47% of respondents to the previous survey (262/553) provided contact information consisting of at least one of the following: email address, telephone number, or mailing address.
The 262 eligible practices were stratified based on specialty (FM or GIM), affiliation (standalone practice or ≥2 practice sites, hereinafter 'multisite practices'), and level of financial decision-making (independent or system). The latter factors were examined because being one of multiple sites or belonging to a healthcare system may affect the level at which purchasing decisions are made -and thus, respondents' knowledge of these decisions -as well as a practice's ability to obtain more favorable pricing or payments based on volume of vaccines administered. We used a quota sampling approach to select practices similar to those responding to our previous survey. First, we established proportional sampling targets based on the number of responses to the previous survey that fell into each of eight specialty/affiliation/decision-making categories. Then, practices in each category for which contact information was provided were approached at random until the target was reached (two of eight categories) or all eligible practices were exhausted (six of eight categories) (Appendix).
Study participants
Individuals were contacted first via e-mail if provided or U.S. mail otherwise to schedule the interviewer-administered survey. Following the first contact, individuals received up to four contact attempts via telephone interspersed with up to three attempts via e-mail or U.S. mail. (Study personnel looked up telephone numbers and mailing addresses for practices that did not provide this information.) If no response was received after these attempts, the physician who provided the contact information was contacted via U.S. mail to request participation of another staff member. Successfully contacted individuals were asked to provide a telephone number and date/time to complete the survey.
The survey was administered January-June 2014. Participants received $75 for their time. The survey was deemed exempt research by the University of Colorado's Institutional Review Board.
Measurements
The survey asked about the respondent's position and involvement in vaccine purchasing and billing for the practice, whether and how the practice bills Medicare Part D, and what percentage of the practice's annual budget goes to adult vaccines. It also included four sets of questions about respondents' experiences with six payer types: private fee-for-service insurance (FFS), private preferred provider organizations (PPO), private health maintenance or managed care organizations (HMO/MCO), Medicaid, Medicare Part B, and Medicare Part D. For each payer, respondents reported payment relative to vaccine purchase prices (less than, about the same, more than); general administration payment for the first vaccine given in a visit (<$11, $11-$17, $18-$24, >$24, too variable to answer); perceived profit on vaccination services (lose money, break even, make a profit); and frequency of claim denial for any reason (frequently, sometimes, rarely, never). The question on perceived profit was also asked about patients who pay out of pocket for vaccination. Respondents were asked to assess profit margin "taking into account what you pay to purchase vaccines, your administration costs, and what you are reimbursed for vaccine cost and administration". For each question set, respondents could report "don't know" or "don't see patients with this insurance type".
Respondents were asked about methods used to purchase private vaccine stocks and to negotiate with private insurance plans regarding vaccination payments. They were also asked whether the practice had stopped purchasing any vaccines for adults, or had stopped vaccinating patients with a particular type of health insurance, due to financial concerns. For all items, respondents were instructed to answer with respect to vaccines routinely recommended for adults ≥19 years other than influenza (i.e. excluding travel vaccines and those given only to pediatric patients). Respondents reported their overall profit margin for seasonal influenza vaccination and non-influenza vaccines separately.
Analysis
Descriptive statistics were calculated using SAS version 9.4; Mantel-Haenszel chi square and Fisher's Exact tests were used to compare responses by specialty, affiliation, and level of financial decision-making. For most items, responses did not differ significantly between FM and GIM; therefore, we present results for both specialties combined. Where responses differed by specialty, we present comparisons and p-values. Results were similar whether analyzed by affiliation or decision-making level; we present findings by affiliation. Findings for specific payer types are restricted to practices reporting they saw patients with, and billed, that insurance.
Results
Description of respondents
Based on predetermined recruitment targets, we approached 242 practices for which we had contact information. Of these, 31 (13%) refused participation and 107 (44%) could not be reached. Staff from 104 practices (43%) completed the survey. The majority of respondents (52%) were office managers or health administrators, 25% were billing staff, and 14% were clinicians. (Table 1) The majority reported submitting vaccine claims or supervising individuals who submit claims, or both; slightly under one-third reported participating in contract negotiations for vaccine purchase or insurance payment. Claims submission and negotiation were more commonly reported by standalone versus multisite practices. Sixtytwo percent of respondents reported participating in decisions about which vaccines to stock. Only 38% reported billing Medicare Part D for adult vaccines, and only 16% reported using TransactRx, which facilitates Part D claims submission by physicians.
Payments for vaccination
For each private payer type, about half of respondents reported payment "about the same" as vaccine purchase price (Table 2 ). Smaller proportions reported payment similar to purchase prices for public payers; Medicaid was the only payer for which the majority of respondents (60%) reported payment less than purchase price. Notably, 26% of respondents said "don't know" when asked about Medicare Part D payments vs. <3% for all other payers. There were no significant differences in response by affiliation.
When asked about vaccine administration payment (Table 3) , a payment range of $11-$17 was reported by about one-third of respondents (31%-34%) for each private payer type and by 26% for Medicare Part B. Medicaid was the only payer for which the majority of respondents (54%) reported vaccine administration payment <$11. For Medicare Part D, equal proportions (18%) reported payments of <$11 and $11-$17; however, one-third of respondents reported not knowing about vaccine administration payment. For all insurance types except Medicare Part B and Medicaid, ≥10% of respondents said payments were too variable to answer the question.
Perceived profit and claim denial
Perceived profit from vaccination varied substantially by payer (Figure 1 ). The largest proportions of respondents perceived making a profit under FFS and PPO plans and from patients paying out-of-pocket; less than one-third of respondents seeing patients in HMO/ MCOs, Medicaid, or Medicare reported profiting on vaccinations. PPOs were the only payer for which a plurality of respondents reported making a profit; the most common response was "break even" for FFS, HMO/MCO, out-of-pocket, and Medicare Part B. Equal proportions of respondents (33%) selected "break even" and "don't know" when asked about vaccination under Medicare Part D. Over half (55%) of respondents reported losing money administering vaccines to Medicaid patients. Taking into account all payer types, fewer than 10% of respondents said they lost money administering vaccines; 37% reported making a profit administering non-influenza vaccines and 50% on seasonal influenza vaccination.
When asked how profit margin for vaccine delivery changed in the past several years, 40% said it stayed the same and 31% said it decreased, while 17% said it increased and 12% did not know. No differences in perceived change in profit margin were noted by affiliation, but FM were less likely than GIM to report decreased profit margin (21% vs. 40%, p<0.05) and more likely to respond "don't know" (19% vs. 4%, p<0.05). About one-third of respondents (31%-38%) reported claims being "frequently" or "sometimes" denied for any reason by most payers. For Medicare Part D, only 24% reported frequent/sometime claim denial, but a higher proportion of respondents (36%) answered "don't know" than for other payers.
Vaccine purchasing practices
Reported frequency of vaccine purchasing and negotiation activities for privately insured patients varied widely between standalone and multisite practices for all items assessed (Table 4) . Strategies most commonly reported by respondents were purchasing from vaccine manufacturers using bulk ordering discounts (60% reported frequently/sometimes doing this), participating in group purchasing organizations for vaccines (59%), and utilizing prompt pay discounts (51%). About one-quarter of respondents reported frequently or sometimes negotiating payments for vaccines or vaccine administration with insurance plans.
Recent changes in vaccine provision
When queried about the past 12 months, 8% of practices reported they stopped purchasing one or more vaccines for adults and 11% reported they stopped giving certain vaccines to patients with particular types of health insurance due to financial concerns, with no differences by affiliation.
Discussion
In this survey of physician practices, perceived payment levels and profit margins for adult vaccination varied widely by payer type. Practices most often reported breaking even on adult vaccination, however the majority perceived financial loss from vaccinating adult Medicaid beneficiaries. Under half of surveyed practices reported billing Part D for vaccinations; less than one-quarter reported routinely negotiating vaccination payments with private insurers. Low utilization of many payment-maximizing strategies, concerns about Medicaid payments, and continued difficulty billing Medicare Part D likely contribute to the perception that vaccinating adults is not profitable for many practices.
Among payer types examined, only PPOs were identified by a plurality of respondents as providing adequate payment to make a profit once vaccination-related costs were taken into account. Although we measured only perceived payments, previous research in pediatric practices found public and private health plans' payments for vaccine administration often did not cover the variable costs of vaccination. (16) The financial feasibility of administering vaccines to adults likely depends on the payer mix in a given practice. Simply breaking even may not provide adequate incentive for physicians to stock and administer vaccines, which pose unique challenges and start-up costs to practices. (17) Vaccine acquisition costs and time to administer and record vaccinations also may affect profit, yet few practices reported regularly negotiating with manufacturers or insurers to reduce vaccine purchase costs or increase payments. It is unclear whether practices are unaware of these strategies or previously employed these strategies but ceased due to a failure to obtain cost savings. Access to discounted vaccine pricing via participation in purchasing groups (reported by 59% of respondents) may obviate the need to negotiate directly with manufacturers. (18) Half of respondents administering influenza vaccine to adults reported making a profit compared with 37% of respondents administering non-influenza vaccines. Influenza vaccines are relatively less expensive than other routinely administered adult vaccines (7), recommended for adults of all ages and health conditions, and ordered and administered annually. Other adult vaccines are less commonly stocked by physicians, particularly GIM, whose patient panels do not include pediatric populations that would routinely receive these vaccines.(4) Physicians may have less experience billing for non-influenza vaccines and may purchase fewer doses for their adult patients, precluding volume ordering discounts. Notably, many vaccine purchasing groups provide discounts even for small-volume purchases; purchasing group participation was common among both FM and GIM respondents. (18) Previous studies showed a lack of knowledge among physicians about Medicare Part D vaccination benefits, corroborating our findings. (3, 15, 19) This is troubling as Part D is intended to cover all recommended vaccines not covered by Medicare Part B, including Tdap and zoster, for which uptake among older adults is low.(1) Provider recommendation is an important predictor of vaccination and standardized vaccination offering may reduce persistent racial/ethnic disparities in adult vaccination uptake (20) , yet imperfect understanding of vaccination benefits or perceived inadequate payments may discourage physicians from recommending vaccines to their adult patients. (15, 21) One study showed FM and GIM prioritize influenza and pneumococcal vaccines over Tdap and zoster and speculated that difficulties billing Medicare Part D accounted for this finding. Strengths of this study include selection of practices to elucidate previous findings (15) and capture variations likely to impact vaccine financing experiences, such as affiliation with multiple sites and membership in a larger organization. Limitations include that data were self-reported and may not accurately reflect practices' income from payers. For example, 48% of respondents reported vaccine administration payments <$18 from Medicare Part B, but the national average Part B payment for vaccine administration in 2013 was $25.86. (23) Nevertheless, perceived payment and profit are important as this may affect how practices choose to provide vaccines to patients. Our participation rate was suboptimal, and sampling focused on factors of interest rather than generalizability, so respondents may not be representative of all FM and GIM in the U.S. Practices that chose to complete our survey may have different experiences with vaccine financing than those not participating. All practices were part of an existing survey network to explore vaccine-related issues; prior work suggests network physicians' responses are similar to those of randomly-selected physicians. (24) We did not assess respondents' vaccine stocking practices, which may influence their perceptions of vaccine financing and reimbursement. Finally, quantitative data support physicians' general perception of low reimbursement for vaccinating Medicaid beneficiaries, but payment rates are established by states and vary from under two dollars to over $30.(10) Our sample size was insufficient to evaluate perceived payment adequacy at the state level.
These findings generally corroborate those of our prior survey, in which physicians reported some level of dissatisfaction with all payers, but particularly Medicare and Medicaid. (15) Similar findings were observed among pediatricians with respect to vaccine administration payments. (25) A persistent lack of knowledge about Medicare vaccination benefits and perceived financial loss from Medicaid could adversely affect provider willingness to vaccinate publicly insured adults, leading to lower vaccination coverage in this population.
(1) CMS issued guidance for physicians in 2007 on how to bill Part D for vaccinations (26) , yet our study and others show continued confusion related to Part D. Organizations representing physicians who treat adult patients are well-positioned to disseminate CMS guidance and provide member education on business practices to mitigate financial burdens of vaccination. The National Adult and Influenza Immunization Summit recently released guidance and resources on vaccine coding and billing that includes information from several national physician groups. (27) Studies by academic or government partners could provide valuable data about the cost to vaccinate adults in various public and private settings and geographic regions; physicians may wish to share observations about their costs of vaccination during scheduled negotiations with insurance plans. Without data on practices' costs to vaccinate adults, insurers cannot evaluate whether vaccination services payments are adequate to compensate physicians for their time and expenses. Finally, public and private stakeholders could collaborate to increase physicians' ease of billing Medicare Part D for vaccinations.
Few practices in our study reported ceasing to provide vaccines to adult patients for financial reasons, consistent with a 2009 study.(17) However, physicians who do not stock a given vaccine may also be less likely to assess patients' needs for that vaccine.(4) Even a small reduction in practice-based vaccine access is concerning given suboptimal adult vaccination coverage and the importance of provider recommendations and offers to optimize vaccine uptake.(6, 28) Despite practices' apparent willingness to continue vaccinating adults for limited financial gain, achieving national goals related to improving vaccine access for adults (29) could be facilitated if targeted information regarding vaccine financing and billing strategies, and assistance implementing the strategies most appropriate to their practices, were available to physicians. Interventions assisting practices to reduce vaccination-associated expenses and obtain full payment for vaccines administered, and to develop referral systems when it is not feasible to offer certain vaccines, could strengthen the U.S. adult vaccination infrastructure and improve access to all ACIP-recommended vaccines for adults.
Supplementary Material
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